Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2018 Sep;46(9):1515-1525.
doi: 10.1016/j.jcms.2018.05.046. Epub 2018 May 31.

Osteonecrosis of the jaw in patients treated with denosumab: A multicenter case series

Suad Aljohani  1 , Robert Gaudin  2 , Julian Weiser  3 , Matthias Tröltzsch  4 , Michael Ehrenfeld  4 , Gabriele Kaeppler  4 , Ralf Smeets  3 , Sven Otto  4
Affiliations
Multicenter Study

Osteonecrosis of the jaw in patients treated with denosumab: A multicenter case series

Suad Aljohani et al. J Craniomaxillofac Surg. 2018 Sep.

Abstract

Purpose: Osteonecrosis of the jaw has been recently reported in patients receiving denosumab for the treatment of metastatic bone disease and osteoporosis. It is essential to investigate this disease as a new osteonecrosis entity in order to recognize its optimal management strategies.

Materials and methods: A total of 63 cases of denosumab-related osteonecrosis of the jaw (DRONJ) diagnosed at two clinical centres were retrospectively reviewed. Demographics, comorbidities, antiresorptive medication use, local preceding event, location, DRONJ stage, treatment and treatment outcomes were analyzed.

Results: In all, 69 MRONJ lesions in 63 patients were diagnosed. The mean patient age was 70 ± 9 years. Denosumab was the only received antiresorptive medication in 50.8% of the patients. Discontinuation of denosumab prior to treatment was recorded for 66.7% of the patients, with a mean period of 6 ± 3.4 months. Stage 2 was the most common stage of the disease (71%). The lesions were predominantly located in the mandible (63.5%). The most common preceding local event was extraction (55.6%). Surgical treatment was performed in 95.7% of the cases, while purely conservative treatment was performed in 4.3%. DRONJ healed after surgical treatment in 71.7% of the treated lesions. Complete mucosal healing was achieved in 77.2% of the lesions treated with fluorescence-guided surgery (17/22). Clinical characteristics and treatment outcomes were not significantly different between patients with and without previous intake of bisphosphonates.

Conclusion: DRONJ is more prevalent at extraction and local infection sites in cancer patients. Within the limitation of this study, surgical treatment, particularly fluorescence-guided surgery, appears to be effective for the management of DRONJ. The prior use of bisphosphonates does not seem to affect severity nor the treatment success rate of DRONJ.

Keywords: ARONJ; DRONJ; Denosumab; Jaw osteonecrosis; MRONJ; ONJ.

PubMed Disclaimer

Publication types

LinkOut - more resources